Related Experiment Videos
Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types
P B Gilbert1, S G Self, M A Ashby
1Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Biometrics
|September 29, 1998
Summary
Assessing human immunodeficiency virus type 1 (HIV-1) vaccine efficacy requires accounting for viral diversity. Statistical methods can infer differential protection based on viral characteristics from clinical trials.
Area of Science:
- Virology
- Immunology
- Biostatistics
Background:
- Human immunodeficiency virus type 1 (HIV-1) exhibits significant genetic diversity.
- Evaluating HIV-1 vaccine efficacy necessitates understanding potential differential protection across viral subtypes.
Purpose of the Study:
- To discuss statistical methodologies for inferring variable vaccine efficacy against different HIV-1 types.
- To analyze data from a randomized, double-blind, placebo-controlled HIV-1 vaccine efficacy trial.
Main Methods:
- Focus on a simplified model where viral characteristics are summarized by a single feature (nominal or scalar).
- Considered discrete categorical and continuous response models.
- Introduced multinomial logistic regression (MLR) for categorical data and a novel semiparametric model for continuous data.
Main Results:
- Identified models where parameters represent log ratios of strain-specific relative risks of infection.
- Demonstrated application of methods to HIV-1 and hepatitis B vaccine trial data.
- The developed statistical models can quantify differential protection.
Conclusions:
- Statistical inference methods can assess how HIV-1 vaccine efficacy varies with viral characteristics.
- These methods are crucial for understanding vaccine performance in diverse populations.
- The study provides a framework for analyzing vaccine efficacy in the context of viral diversity.